Comparative Pharmacology
Head-to-head clinical analysis: EMERPHED versus LORATADINE AND PSEUDOEPHEDRINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMERPHED versus LORATADINE AND PSEUDOEPHEDRINE SULFATE.
EMERPHED vs LORATADINE AND PSEUDOEPHEDRINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Loratadine: Selective peripheral H1-receptor antagonist, reducing histamine-mediated allergic responses. Pseudoephedrine sulfate: Indirect sympathomimetic, releasing norepinephrine from presynaptic terminals, causing vasoconstriction and decongestion.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
One tablet (loratadine 5 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours. Maximum: 2 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Loratadine: 8-14 hours (terminal); its active metabolite descarboethoxyloratadine: 17-24 hours. Pseudephedrine sulfate: 5-8 hours (dependent on urine pH; alkaline urine prolongs half-life).
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Loratadine and its metabolites are primarily excreted in urine (approximately 80%) and feces (approximately 20%). Pseudephedrine is predominantly excreted unchanged in urine (70-90%), with the remainder as inactive metabolites.
Category C
Category A/B
Sympathomimetic
Sympathomimetic